Digoxin use and adverse outcomes in patients with atrial fibrillation

Medicine (United States)

Volumn 95, Issue 12, 2016, Pages

  Zeng, Wu Tao ^a   Liu, Zhi Hao ^a   Li, Zhu Yu ^a   Zhang, Ming ^b   Cheng, Yun Jiu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN;

ADVERSE OUTCOME; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DEATH; DRUG SAFETY; DRUG USE; HEART FAILURE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; CAUSE OF DEATH; MORTALITY; RISK; SURVIVAL RATE;

ATRIAL FIBRILLATION; CAUSE OF DEATH; DIGOXIN; HUMANS; RISK; SURVIVAL RATE;

EID: 84962170632     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002949     Document Type: Review

References (22)

1. January CT, Wann LS, Alpert JS, et al. 2014AHA/ACC/HRS Guideline for the Management of Patients with Aatrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.
2. Camm AJ, Savelieva I, Lip GY. Rate control in the medical management of atrial fibrillation. Heart. 2007;93:35-38.
3. Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28:527-535.
4. Freeman JV, Reynolds K, Fang M, et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8:49-58.
5. Okin PM, Hille DA, Wachtell K, et al. Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. J Hyper-tens. 2015;33:1480-1486.
6. Wang J, Yang YM, Zhu J, et al. Analysis of risk factors for all cause-mortality in Chinese emergency atrial fibrillation patients. Zhonghua Yi Xue Za Zhi. 2013;93:2871-2875.
7. Allen LA, Fonarow GC, Simon DN, et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65:2691-2698.
8. Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385:2363-2370.
9. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64:660-668.
10. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712-716.
11. Zeng WT, Sun XT, Tang K, et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease. Stroke. 2015;46:157-163.
12. Cheng YJ, Liu ZH, Yao FJ, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013;10:e1001515.
13. Cheng YJ, Nie XY, Chen XM, et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol. 2015;66:2173-2184.
14. Cheng YJ, Zhang J, Li WJ, et al. More favorable response to cardiac resynchronization therapy in women than in men. Circ Arrhythm Electrophysiol. 2014;7:807-815.
15. Xie W, Santulli G, Reiken SR, et al. Mitochondrial oxidative stress promotes atrial fibrillation. Sci Rep. 2015;5:11427.
16. D'Ascia SL, D'Ascia C, Marino V, et al. Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy. Int J Clin Pract. 2011;65:1149-1155.
17. Xie W, Santulli G, Guo X, et al. Imaging atrial arrhythmic intracellular calcium in intact heart. J Mol Cell Cardiol. 2013;64:120-123.
18. Chirinos JA, Castrellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2005;2:525-529.
19. Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart. 2008;94:191-196.
20. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1973-1980.
21. Adams KJ, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46:497-504.
22. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652-1658.